EFFICACY OFINFLIXIMABIN THE TREATMENTOF CROHN’S DISEASEIN CHILDREN

Voprosy Sovremennoj Pediatrii

卷:11

M. M. Venedictova¹  F. F. Shavrov²  A. S. Potapov²  E. G. Tsimbalova² 

[1] I.M. Sechenov First Moscow State Medical University, Moscow;

[2] Scientific Research Center of Children’s Health RAMS, Moscow;

关键词: children;    crohn’s disease;    treatment with infliximab;   

DOI  :  10.15690/vsp.v11i1.145

来源: DOAJ

【 摘 要 】

This paper shows the research results of the biological therapy with chimeric monoclonal antibody to tumor necrosis factor (TNF)(infliximab). 33 children aged 6 to 18 years with various forms of Crohn’s disease were enrolled in the study. Therapy duration ranged from 3 months to 1 year or more. After the induction course of therapy efficacy was 94%, clinical remission was achieved in 70% of patients, after 1 year of therapy efficacy of therapy was reduced to 84%, clinical remission was observed in 70% of children. Endoscopic remission rate after induction was observed in 24% of children, and in 29% after 54 weeks of therapy. After one year of treatment in 9 out of 11 children glucocorticoid therapy was completely stopped. Adverse events after infliximab administration were observed in 9% of children. One child was withdrawn from the study due to infliximab intolerance.

【 授权许可】

Unknown